Market Overview

UPDATE: Credit Suisse Assumes Coverage on Laboratory Corp. of America Holdings with Neutral Rating, $95 PT

Related LH
25 Tactical Trades Goldman Sachs Is Watching Amid Earnings Season
14 Healthcare Stocks Fundstrat Is Buying

In a report published Friday, Credit Suisse assumed coverage on Laboratory Corp. of America Holdings (NYSE: LH) with a Neutral rating and $95.00 price target.

Credit Suisse noted, “We are assuming coverage of LH, maintaining the previous Neutral rating. Recall LH is the second largest independent clinical laboratory in the U.S. with ~10% market share. We acknowledge the company enjoys industry leading margins driven in large part by its IT and automation efforts, but despite its strong operations & execution track record, we believe the industry currently faces multiple top-line headwinds. Moreover, with LabCorp currently trading at 12.9x our F13 EPS estimate and 7.5x our F13 EBITDA estimate, roughly in line with historic averages, we believe the current risk/reward profile is more balanced.”

Laboratory Corp. of America Holdings closed on Thursday at $90.46.

Latest Ratings for LH

Jun 2015KeyBancInitiates Coverage onOverweight
Apr 2015JP MorganMaintainsOverweight
Apr 2015JefferiesMaintainsHold

View More Analyst Ratings for LH
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Analyst Ratings


Related Articles (LH)

View Comments and Join the Discussion!

Get Benzinga's Newsletters